Last reviewed · How we verify
Lu AF28996
At a glance
| Generic name | Lu AF28996 |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Lu AF28996 in Participants With Parkinson's Disease (PD) (PHASE1)
- A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men (PHASE1)
- A Trial Investigating Lu AF28996 in Healthy Adult Participants (PHASE1)
- A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD) (PHASE1)
- Single Dose of Lu AF28996 to Healthy Young Men (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lu AF28996 CI brief — competitive landscape report
- Lu AF28996 updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI